- Report
- June 2024
- 182 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- October 2022
- 118 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- November 2023
- 90 Pages
France
From €3186EUR$3,500USD£2,706GBP
- Report
- June 2022
- 96 Pages
Global
From €3500EUR$4,119USD£3,077GBP
- Report
- February 2022
- 227 Pages
Global
From €2365EUR$2,598USD£2,009GBP
€3379EUR$3,712USD£2,870GBP
- Book
- November 2024
- 464 Pages
- Book
- July 2022
North America
Engineered T Cells are a type of biotechnology that involves the genetic engineering of a patient's own T cells to create a personalized therapy for the treatment of cancer and other diseases. This technology is based on the idea of using the body's own immune system to fight disease. The engineered T cells are modified to recognize and attack cancer cells, while leaving healthy cells unharmed. This technology has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma.
Engineered T Cells are a rapidly growing field of biotechnology, with many companies developing new treatments and therapies. Companies such as Kite Pharma, Juno Therapeutics, and Novartis are leading the way in this field, developing innovative treatments and therapies for cancer and other diseases. Other companies such as Cellectis, Bluebird Bio, and Bellicum Pharmaceuticals are also making significant contributions to the field. Show Less Read more